Skip to main content

Safe Medical inaugurates its Integrated Innovation and Production Centre (CIPI) on the Fleurieux-sur-l’Arbresle (69) industrial site

Written by Customer Service on . Posted in Public Companies.

 

 

Safe Medical inaugurates its Integrated Innovation and Production Centre (CIPI) on the Fleurieux-sur-l’Arbresle (69) industrial site

 

  • A titanium 3D printing module and a clean room dedicated to packaging complete the existing facilities
  • 2.5M€ have been invested in the Safe Medical site since its acquisition by Safe Orthopaedics in 2020
  • A leading industrial complex in Europe for the innovation and production of orthopedic surgery medical devices

 

     

Éragny-sur-Oise, Fleurieux-sur-l’Arbresle, October 13, 2021 at 5:45 pm CET – Safe Orthopaedics (FR0013467123 – ALSAF), a company specializing in the design, manufacture and marketing of ready-to-use technologies for back surgery, particularly safe for emergency-treated vertebral fractures, has announced the inauguration of its Center for Innovation and Integrated Production (CIPI), on the Fleurieux-sur-l’Arbresle (69) industrial site. Operational since September, the CIPI includes two clean rooms dedicated to the packaging of medical devices and a titanium 3D printing module for the design of implants and surgical tools. It complements the production lines and the R&D unit set up in 2020 and entirely dedicated to orthopedic surgery.

Safe Orthopaedics acquired Safe Medical (Ex-LCI Medical) in 2020. Since then, the company has invested €2.5 million in the Fleurieux-sur-l’Arbresle site, making it a leading industrial complex in Europe for the innovation and production of medical devices for orthopedic surgery. One million euros were devoted to the renovation and extension of the buildings, and nearly 1.5 million to the technological re-equipment of the site (1.5 million euros). The Safe Group received support from Bpifrance for this project, via a €0.8 million innovation loan.

The activity of the Safe Medical site is driven by the recovery of the subcontracting activity, with volumes now higher than their pre-crisis level, and by the internationalisation of the production of Safe Orthopaedics’ proprietary innovations.

Pierre Dumouchel, Chairman and CEO of Safe Orthopaedics, said: “We are delighted that our Integrated Innovation and Production Centre (CIPI) is now up and running, in line with the timetable we set ourselves a year ago when we launched the work. The integration of the entire value chain, from R&D to manufacturing, on the same site allows us to streamline our processes, with an economic and environmental impact, while also giving us the means to radically accelerate the innovation cycle. We will continue to invest in the Fleurieux-sur-l’Arbresle site to maintain the excellence of this industrial site and ensure our leadership in spine surgery.”

About Safe Group
Safe Group is a French medical technology group that brings together Safe Orthopaedics, a pioneer in ready-to-use technologies for spine pathologies, and Safe Medical (formerly LCI Medical), a subcontractor of medical devices for orthopedic surgery. The group employs approximately 150 people.

Safe Orthopaedics develops and manufactures kits combining sterile implants and single-use instruments, available at any time to the surgeon. These technologies are part of a minimally invasive approach aimed at reducing the risk of contamination and infection, for the benefit of the patient and with a positive impact on hospitalization times and costs.  Protected by 18 patent families, SteriSpineTM kits are CE marked and FDA approved. Safe Orthopaedics is headquartered in the Paris region (Eragny-sur-Oise (95610)) and has subsidiaries in the United Kingdom, Germany, the United States and the Lyon region (Fleurieux-sur-l’Arbresle).

For more information: www.safeorthopaedics.com

Safe Medical produces implantable medical devices and ready-to-use instruments. It has an innovation centre and two production sites in France (Fleurieux-sur-l’Arbresle, 69210) and Tunisia, offering a wide range of industrial services: design, industrialisation, machining, finishing and sterile packaging. Supported by the French recovery plan in 2020, the company invests in additive printing and will be operational in 2022 on this new technology.

For more information: www.safemedical.fr

Contacts 

Safe Orthopaedics                                                                                    

François-Henri Reynaud                  
Chief Financial and Administrative Officer                    
Tél. : +33 (0)1 34 21 50 00                              
investors@safeorthopaedics.com           

Press Relations
Ulysse Communication
Pierre-Louis Germain / +33 (0)6 64 79 97 51 / plgermain@ulysse-communication.com
Bruno Arabian / +33 (0)6 87 88 47 26 / barabian@ulysse-communication.com

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.